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Objectives: In December 2010, there was an outbreak of acute febrile respi-
ratory disease in many Korean military camps that were not geographically
related. A laboratory analysis confirmed a number of these cases to be infected
by the pandemic influenza A(H1N1) 2009 (H1N1pdm09) virus. Because mass
vaccination against H1N1pdm09 was implemented at the infected military
camps eleven months ago, the outbreak areas in which both vaccinated and
nonvaccinated individuals were well mixed, gave us an opportunity to evaluate
the effectiveness of H1N1pdm09 vaccine through a retrospective cohort study
design.
Methods: A self-administered questionnaire was distributed to the three military
camps in which the outbreak occurred for case detection, determination of
vaccination status, and characterization of other risk factors. The overall
response rate was 86.8% (395/455). Case was defined as fever (38 C) withted under the terms of the Creative Commons Attribution Non-Commercial License (http://
0) which permits unrestricted non-commercial use, distribution, and reproduction in any
roperly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
210 K.-H. Kim, et alcough or sore throat, influenza-like illness (ILI), and vaccination status verified by
vaccination registry. Crude vaccine effectiveness (VE) was calculated as “1 
attack rate in vaccinated individuals/attack rate in nonvaccinated individuals”,
and adjusted VE was calculated as “1 e odds ratio” using logistic regression
adjusted for potential confounding factor. A number of ILI definitions were used
to test the robustness of the result.
Results: The attack rate of ILI was 12.8% in register-verified vaccinated individuals
and24.0% in nonvaccinated individuals. The crudeVEwas thus calculated tobe46.8%
[95% confidence interval (CI): 14.5e66.9]. The adjusted VE rate was 46.8% (95%
CI:e9.4 to 74.1). Various combinations of ILI symptoms also showed similar VE rates.
Conclusion: We evaluated the effectiveness of H1N1pdm09 vaccine in the 2010e
2011 season in an outbreak setting. Although the result was not sensitive to any
analytical method used and ILI case definition, the magnitude of effectiveness was
lower than estimated in the 2009e2010 season.1. Introduction
In December 2010, there was an outbreak of acute
febrile respiratory disease in several Korean military
camps that were not geographically related. An initial
outbreak assessment showed that in each camp there
were more than 10 cases with fever over 38 C and
respiratory disease for a few days. A laboratory exam-
ination confirmed influenza A(H1N1)pdm09 infection in
some cases, and therefore, the authorities declared the
outbreak as sporadic.
This outbreak provided an opportunity to evaluate the
effectiveness of A(H1N1)pdm09 vaccine under the
following conditions. First, the Korean military con-
ducted a mass vaccination drive from January 2010 in
order to protect its soldiers from H1N1pdm09 infection,
and no seasonal influenza vaccination was administered
except for new recruits and medical staff. Second, the
medical history and vaccination history of the in-
dividuals was collected from medical records in the
camps. Third, the cases lived in the same barrack, and
therefore were considered to be exposed to the
H1N1pdm09 virus, and were in a steady group with no
huge external effect because they had restricted contacts
with outside groups.
This environment and the characteristics of military
camps were enough to fulfill the basic condition
required to evaluate the effect of vaccination during an
outbreak [1,2]. Previous research evaluating the effec-
tiveness of H1N1pdm09 vaccine were mainly laboratory
studies [3e6] or large-scale cohort studies [7e11].
Although few studies have been reported based on
outbreak cases, studies on evaluating the effectiveness
of vaccine 1 year after vaccination for H1N1pdm09 are
rare [12,13]. This study was conducted to complement
previous studies on the vaccination effect of
H1N1pdm09.
Therefore, the authors aimed to evaluate the vacci-
nation effect of H1N1pdm09 using a retrospective
cohort study design on a sporadic outbreak case, basedon the aforementioned conditions and potential
implications.
2. Materials and Methods
2.1. Situation
The Korean military conducted a mass vaccination
drivedGreen Flu-S Plus vaccine that had antigen (3.25
mg) and MF-58 adjuvantdagainst H1N1pdm09 infec-
tion from January 2010 to March 2010. The immuno-
genicity of the vaccine was confirmed in a previous
study [6]. Since then, with no additional vaccination of
H1N1pdm09, half of the vaccinated soldiers were dis-
charged at the end of their service term and an equal
number of new recruits were placed at the camps with
no history of vaccination against the virus. Each camp
had recruited a number of susceptible individuals. The
three camps were independent units with no geograph-
ical or administrative relation.
2.2. Patients
The study patients were soldiers stationed at the three
military camps as of December 1, 2010. The authors
distributed self-administered questionnaires and
reviewed the medical records of the soldiers to check
their vaccination history. Informed consents were ob-
tained from all the study participants. The questions
included symptoms (fever, body temperature, cough,
sore throat, running nose, chill, and muscle pain),
vaccination history of seasonal influenza, vaccination
history of H1N1pdm09, previous diagnosis of
H1N1pdm09 infection, smoking, body mass index
(BMI), frequency of hand washing, underlying diseases,
and sociodemographic factors.
2.3. Definition of variables
Case included those individuals who reported fever
(38 C) with cough or sore throat, or those who had
been treated for the same symptoms in December 2010.
This definition corresponded to influenza-like illness
(ILI) defined by the Korea Centers for Disease Control
Effectiveness of pandemic influenza A(H1N1) 2009 vaccine 211and Prevention (KCDC). The H1N1pdm09 vaccination
status was defined as follows: registry verified vacci-
nation, self reported vaccination (non-verified), non
vaccination.2.4. Analysis
The epidemic curve of each camp was recorded
everyday (Figure 1), and the sociodemographic charac-
teristics of each camp were tabulated (Table 1). Among
the sociodemographic characteristics and influenza-VEZ

1 attack rate of registry verified vaccinated individuals
attack rate of nonvaccinated or self -reported vaccinated individuals

 100associated factors, we identified the variables related
to the vaccination history by Chi-square test. The
associated variables were considered to be confounding
factors in evaluating the effectiveness of vaccination.
Vaccination effectiveness was evaluated by crude
analysis, stratified analysis, and multivariate analysis.
We evaluated the crude vaccine effectiveness (VE) by
comparing the incidence based on the vaccination status
with the following formula [1]:
We then calculated the crude VE by stratifying the
sociodemographic characteristics and influenza-
associated factors. In the multivariate analysis, we
included age, smoking status, BMI, seasonal influenza
vaccinations status, and H1N1pdm09 vaccination
status.
Because we used the nonspecific clinical symptoms
in the case definition, we estimated the vaccination
effectiveness with various case definitions [e.g., cases
with fever 37.8 C or 38 C in the medical record]
and compared those with the VE of our case definition.
This was conducted to evaluate the robustness of the0
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Figure 1. Epidemic curves of influenza-lresults of this study, that is, a kind of sensitivity
analysis.2.5. Ethical considerations
Although this study does not require an Institutional
Review Board (IRB) consideration, as it was conducted
as part of an epidemiological investigation of a respi-
ratory outbreak in military camps, it contained a sus-
ceptible study group. Therefore, this study was reviewed
by the Korean Military IRB. We distributed the studyplan to all the study participants and received informed
consents. To acknowledge their participation in the
study, the participants were provided with a present.3. Results
As of December 1, 2010, there were a total of 455
candidates in the three military camps, and among them,
395 participated in this study (participant rate: 86.8%).
A total of 50 persons rejected participation and 10 were
unable to attend the interview, because they were un-
available in their respective camps during the study.
3.1. Outbreak situation
A total of 77 cases in three units were identified and
the incidence rate was 19.5%. The incidence rate of
Units A, B, and C was 14.6% (36/247), 29.0% (27/93),
25.5% (14/55), respectively. Each unit’s incidence
aspect is shown in Figure 1. Although the outbreak
period was different, the progress of the outbreak was
similar with a single peak.51 52 53 Weeks
Unit C
Unit B
Unit A
ike illness by military units (A, B, C).
Table 1. Details for pandemic influenza A(H1N1) ILI cases and controls
Case Control
pN Z 77 (100%) N Z 318 (100%)
Unit
A (247) 36 (47) 211 (66) 0.005
B (93) 27 (35) 66 (21)
C (55) 14 (18) 41 (13)
Age (y)
19 13 (17) 37 (12) 0.263
20e24 56 (72) 230 (73)
25e53 8 (10) 51 (16)
Day of military recruitment
Prior to 2010 34 (44) 190 (60) 0.013
After 2010 43 (56) 128 (40)
Smoking history
Current smoker 26 (34) 166 (52) 0.004
Nonsmoker/ex-smoker (1 mo) 51 (66) 152 (48)
Body mass index
<23 53 (69) 173 (54) 0.066
23e24.9 13 (17) 86 (27)
25 11 (14) 59 (19)
Past history of dx on influenza A(H1N1)pdm09
Yes 3 (4) 13 (4) 0.939
No 74 (96) 305 (96)
Past history of seasonal influenza vaccination (recent 1 y)
Yes 5 (6) 22 (7) 0.895
No 72 (94) 296 (93)
Past history of influenza A(H1N1)pdm09 vaccination
Yes Registry-verified 19 (25) 130 (41) 0.031
Self-report 29 (38) 96 (30)
No 29 (38) 92 (29)
Data are presented as n (%). ILI Z influenza-like illness; dx Z diagnosis for influenza A(H1N1)pdm09 infection.
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25 years, and all were men except one. The number
of recruits admitted prior to January 1, 2010, who were
supposed to have H1N1pdm09 vaccination in the
camp, was 224 (56.7%). A total of 16 soldiers (4%)
were treated for H1N1pdm09 infection prior to joining
the military camp, and 27 (6.8%) had seasonal influ-
enza vaccination in the past 1 year. The vaccination
rate of H1N1pdm09 as verified by the registry was
37.7% (149/395). However, it will increase up toTable 2. Number of pandemic influenza A(H1N1) ILI cases acc
and adjusted) estimates*
Vaccination status Case/control
Vaccination 1 No þ self-reported 58/188 (23.
Registry verified 19/130 (12.
Vaccination 2 No 29/92 (24.0
Registry verified 19/130 (12.
*Case included patients who had influenza-like illness (38 C and cough/sore
age group, smoking history, BMI, seasonal influenza vaccination history (past
mass index; CI Z confidence interval; ILI Z influenza-like illness; VE Z va69.3% (274/395) if the soldiers who checked the
vaccination history in the questionnaires were also
included (Table 1).
3.2. Effectiveness of influenza vaccine
Crude VE was 45.9% [95% confidence interval (CI):
12.9e66.4], and the risk to get infected with ILI in the
vaccinated group decreased by about half. If adjusted by
age, smoking history, BMI, seasonal influenza vacci-
nation history, H1N1pdm09 infection, the crude VE wasording to vaccination status and vaccine effectiveness (crude
[n (%)]
Crude VE (%)
(95% CI)
Adjusted VEy (%)
(95% CI)
6/76.4) 45.9 47.3
8/87.2) (12.9e66.4) (4.1e71.0)
/76.0) 46.8 46.8
8/87.2) (9.9e68.6) (9.4 to 74.1)
throat), which is either self-reported or medically attended; yAdjusted for
1 year), past influenza A(H1N1)pdm09 diagnosis history. BMI Z body
ccine effectiveness.
Table 3. Sensitivity analysis of vaccine effectiveness according to case definition
Case definition
Crude VE % (95% CI)
Vaccination 1* Vaccination 2y
ILI 45.9 (12.9e66.4) 46.8 (9.9e68.6)
ILI MA 46.2 (5.2e69.5) 45.9 (1.9e71.2)
ILI SR 49.2 (14.4e69.9) 50.0 (11.2e71.9)
Fever 38.0 C 43.1 (9.3e64.3) 44.0 (6.1e66.6)
Cough 46.9 (27.2e61.3) 51.3 (31.8e65.2)
*Comparing “no” or “self-reported” vaccination with “registry-verified” vaccination; yComparing “no” vaccination with “registry-verified” vaccination.
CIZ confidence interval; ILIZ all influenza-like illnesses (38 C and cough/sore throat), which are self-reported cases or medically attended cases;
ILI MAZ influenza-like illness (38 C and cough/sore throat), which is a medically attended case only; ILI SRZ influenza-like illness (38 C and
cough/sore throat), which is a self-reported case only; VE Z vaccine effectiveness.
Effectiveness of pandemic influenza A(H1N1) 2009 vaccine 21347.3% (95% CI: 4.1e71.0), and the risk to get ILI in the
vaccinated group decreased similarly. A similar result
(46.8%) was obtained if we exclude the unconfirmed
H1N1pdm09 vaccination with no confirmation in the
registry (Table 2). If various ILI definitions were
applied, we had various incidence rates, but the values
of vaccination effectiveness were relatively consistent.
If loose case definition was applied (lowering the fever
temperature or containing nonspecific symptoms only),
the incidence rates were increasing, but the values of
vaccination effectiveness were consistent. By contrast, if
strict case definition was applied, the incidence rates
decreased, but the vaccination effectiveness was not
much different with that of the original setting (Table 3).4. Discussion
The H1N1pdm09 vaccine administered in January
2010 has about 50% effectiveness on the H1N1pdm09
outbreak that occurred in December 2010. The magni-
tude of vaccination effectiveness was robust with no
huge difference, even when multivariate analysis was
applied and various ILI definitions were adopted.
The magnitude of VE in this study was lower than the
2009e2010 H1N1pdm09 season in the previous studies,
which reported a 70%magnitude.However, themagnitude
in this study was similar to that calculated for the next
season (2010e2011) in the previous studies. Studies to
evaluate the vaccination effectiveness 1 year after vacci-
nation had suggested the hypothesis that the vaccination
effectiveness was not persistent because no statistically
significant results were available [12,13]. However, this
study showed that statistically significant vaccination
effectiveness does exist even 1 year after vaccination. The
study result was immunologically consistent with a pre-
vious antigenicity study in which the vaccination effec-
tiveness was noted even 1 year after seasonal influenza
vaccination, but with decreased antibody titer [14].
This study was designed and conducted to evaluate
the vaccination effectiveness of H1N1pdm09 and
methodologically makes up for the previous studies withcase-control designs. In case-control study, exposure to
a pathogen in the two groups is put artificially similar or
is assumed to be similar. In this study, the study par-
ticipants shared living space and contacted frequently,
and therefore, we could assume that they were all
similarly exposed to the pathogen regardless of vacci-
nation status, which is the major explanatory variable.
Using various combinations of case definition based on
various body symptoms, respiratory symptoms, treat-
ment status, and ILI confirmation status, the incidence
rates of the vaccinated group were found to be lower
than those of the nonvaccinated group. Although some
CIs include the null value, no combination was statis-
tically significant in the direction of effectiveness. This
implied that the results of this study were not by chance,
but were rather very robust. While interpreting the re-
sults of this study, the following should be considered.
First, the case definition in this study was not that of a
laboratory test but was a nonspecific one based on ILI
symptoms, and so it could underestimate the vaccination
effectiveness as in general studies with information
misclassification [15,16]. However, the magnitude was
considered minimum for the following reasons: First, a
laboratory analysis confirmed all the cases to be
H1N1pdm09 infected. Second, considering the aspect of
outbreak, a single pathogen was suspected. Third, ac-
cording to the KCDC influenza laboratory surveillance
report, 95% of respiratory infection was due to
H1N1pdm09 infection [17]. Fourth, the vaccination
effectiveness under various case definitions was rela-
tively consistent. Although the case definition was not
based on the confirmative result of laboratory test, the
aforementioned situations strongly suggested that the
vaccination effectiveness in this study was not for ILI
but for H1N1pdm09.
Next, we needed to evaluate the intergroup hetero-
geneity (study participants, type of exposure, method to
measure the result) in order to review the validity of
pooled analysis. The study participants from the three
groups were all men in their early 20s, shared camp
lives, and were vaccinated with the same vaccine during
the H1N1pdm09 mass vaccination drive. In addition, the
214 K.-H. Kim, et alaspect of outbreak was similar. The results were
measured with the same questionnaire. Therefore, we
thought that this study evaded any critical fault to sus-
pect the results of pooled analysis.
Finally, with regard to the external validity, the re-
sults of this study could not be applied to other age
groups as well, especially to the elderly individuals who
have low vaccination effectiveness. In this study, all the
participants were young adult men. As for the internal
validity, the study participants were homogeneous, a
factor which enhanced the internal validity.
Although there were some limitations, this study
complemented the previous studies in study design and
duration of effectiveness by evaluating the effectiveness
of H1N1pdm09 vaccine 1 year after vaccination in
military camps during an outbreak. The strength of this
study was that the vaccination effectiveness was robust
regardless of case definitions and analytical models, and
that we considered other factors that could possibly
affect influenza outbreak in our analysis.
In conclusion, the effectiveness of H1N1pdm09
vaccine 1 year after vaccination was approximately
47%, and this study confirmed the results of previous
studies, which showed that vaccination effectiveness
decreased as time passed.Acknowledgments
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